Synlogic, Inc. – NASDAQ:SYBX
Synlogic stock price today
Synlogic stock price monthly change
Synlogic stock price quarterly change
Synlogic stock price yearly change
Synlogic key metrics
Market Cap | 16.30M |
Enterprise value | 47.52M |
P/E | -0.57 |
EV/Sales | 30.15 |
EV/EBITDA | -0.50 |
Price/Sales | 27.34 |
Price/Book | 0.52 |
PEG ratio | -0.03 |
EPS | -10.09 |
Revenue | 3.20M |
EBITDA | -50.52M |
Income | -73.22M |
Revenue Q/Q | -95.40% |
Revenue Y/Y | 188.73% |
Profit margin | -6198.35% |
Oper. margin | -6294.48% |
Gross margin | 9.64% |
EBIT margin | -6294.48% |
EBITDA margin | -1576.35% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSynlogic stock price history
Synlogic stock forecast
Synlogic financial statements
| Jun 2023 | 35K | -15.04M | -42994.29% |
|---|---|---|---|
| Sep 2023 | 393K | -12.07M | -3073.28% |
| Dec 2023 | 2.76M | -14.53M | -524.88% |
| Mar 2024 | 8K | -31.56M | -394550% |
| 2025 | 4.47M | -11.5M | -256.81% |
|---|---|---|---|
| 2026 | 22.75M | -76.43M | -335.97% |
| 2027 | 83.24M | -7.99M | -9.61% |
| 2028 | 232.98M | 39.92M | 17.14% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -2.55 | -2.57 |
|---|---|---|
| 2024-03-19 | -1.11 | -1.71 |
| Jun 2023 | 79284000 | 24.51M | 30.91% |
|---|---|---|---|
| Sep 2023 | 66254000 | 22.85M | 34.49% |
| Dec 2023 | 75550000 | 32.89M | 43.54% |
| Mar 2024 | 36057000 | 22.73M | 63.04% |
| Jun 2023 | -11.62M | 31.95M | 389K |
|---|---|---|---|
| Sep 2023 | -12.95M | -8.83M | 62K |
| Dec 2023 | -5.52M | -14.62M | 19.58M |
| Mar 2024 | -15.43M | 16.28M | 16K |
Synlogic alternative data
| Aug 2023 | 72 |
|---|---|
| Sep 2023 | 72 |
| Oct 2023 | 72 |
| Nov 2023 | 72 |
| Dec 2023 | 72 |
| Jan 2024 | 72 |
| Feb 2024 | 72 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
Synlogic other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 560 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DOOLEY MARY BETH officer: Head of Finance | Common Stock | 188 | $1.73 | $325 | ||
Sale | AWAD ANTOINE officer: Chief Op.. | Common Stock | 372 | $1.73 | $644 | ||
Sale | BRENNAN AOIFE director, officer: See Remarks | Common Stock | 19,042 | $0.58 | $10,968 | ||
Sale | AWAD ANTOINE officer: Chief Op.. | Common Stock | 6,438 | $0.58 | $3,708 | ||
Sale | JENSEN MICHAEL VANGSTED officer: Chief Financial Officer | Common Stock | 2,553 | $0.58 | $1,471 | ||
Purchase | JENSEN MICHAEL VANGSTED officer: Chief Financial Officer | Common Stock | 9,500 | $1.12 | $10,640 | ||
Sale | AWAD ANTOINE officer: Chief Op.. | Common Stock | 2,650 | $2.45 | $6,482 | ||
Sale | BRENNAN AOIFE director, officer: President an.. | Common Stock | 8,894 | $2.45 | $21,755 | ||
Purchase | SHEA RICHARD P director | Common Stock | 7,500 | $2.74 | $20,550 | ||
Sale | MILLER PAUL FRANCIS officer: Chief Scientific Officer | Common Stock | 5,849 | $9.75 | $57,028 |
| Patent |
|---|
Application RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES AND DISORDERS ASSOCIATED WITH AMINO ACID METABOLISM AND METHODS OF USE THEREOF Filling date: 11 Jan 2017 Issue date: 19 Sep 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 17 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 10 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc (1976) Pres, Chief Executive Officer & Director | $811,300 |
| Mr. Antoine Awad (1980) Chief Operating Officer | $518,420 |
-
What's the price of Synlogic stock today?
One share of Synlogic stock can currently be purchased for approximately $1.45.
-
When is Synlogic's next earnings date?
Unfortunately, Synlogic's (SYBX) next earnings date is currently unknown.
-
Does Synlogic pay dividends?
No, Synlogic does not pay dividends.
-
How much money does Synlogic make?
Synlogic has a market capitalization of 16.30M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 185.68% to 3.37M US dollars. Synlogic made a loss 57.28M US dollars in net income (profit) last year or -$1.71 on an earnings per share basis.
-
What is Synlogic's stock symbol?
Synlogic, Inc. is traded on the NASDAQ under the ticker symbol "SYBX".
-
What is Synlogic's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Synlogic?
Shares of Synlogic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Synlogic's key executives?
Synlogic's management team includes the following people:
- Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc Pres, Chief Executive Officer & Director(age: 49, pay: $811,300)
- Mr. Antoine Awad Chief Operating Officer(age: 45, pay: $518,420)
-
How many employees does Synlogic have?
As Jul 2024, Synlogic employs 6 workers.
-
When Synlogic went public?
Synlogic, Inc. is publicly traded company for more then 9 years since IPO on 30 Sep 2015.
-
What is Synlogic's official website?
The official website for Synlogic is synlogictx.com.
-
Where are Synlogic's headquarters?
Synlogic is headquartered at 301 Binney Street, Cambridge, MA.
-
How can i contact Synlogic?
Synlogic's mailing address is 301 Binney Street, Cambridge, MA and company can be reached via phone at +61 74019975.
Synlogic company profile:
Synlogic, Inc.
synlogictx.comNASDAQ
6
Biotechnology
Healthcare
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
CIK: 0001527599
ISIN: US87166L2097
CUSIP: 87166L100
